ம்ட் ஸ்டான்போர்ட் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ம்ட் ஸ்டான்போர்ட் பல்கலைக்கழகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ம்ட் ஸ்டான்போர்ட் பல்கலைக்கழகம் Today - Breaking & Trending Today

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care


May 27, 2021
Adding dapagliflozin to standard heart failure therapies provides “intermediate value” for American patients who have heart failure with reduced ejection fraction (HFrEF), a new cost-effectiveness analysis suggests at odds with earlier analyses that suggested the cost per quality-adjusted life-year (QALY) would be below the accepted $50,000 cutoff.
That’s because earlier studies, focused on settings outside the United States, considered both the “markedly lower” costs of the drug in countries like the United Kingdom, Germany, and Spain, as well as the lower overall healthcare costs in those nations, investigators led by Justin Parizo, MD (Stanford University, CA), say.
“Cost-effectiveness analyses are inherently tied to the society in which they’re evaluated,” senior author Alexander Sandhu, MD (Stanford University), explained to TCTMD. “While the clinical benefits might be quite similar across different contexts and populations, the cost ....

United States , United Kingdom , Justin Parizo , Alexander Sandhu , Daniel Mark , Centers For Disease , Drug Administration , Md Stanford University , Duke Clinical Research Institute , American College Of Cardiology Heart Association , Stanford University , Disease Control , American College , American Heart Association , Derek Chew , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , அலெக்சாண்டர் சந்து , டேனியல் குறி , மையங்கள் க்கு நோய் , ம்ட் ஸ்டான்போர்ட் பல்கலைக்கழகம் , டியூக் மருத்துவ ஆராய்ச்சி நிறுவனம் , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் இதயம் சங்கம் , ஸ்டான்போர்ட் பல்கலைக்கழகம் , நோய் கட்டுப்பாடு , அமெரிக்கன் கல்லூரி ,

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs


May 18, 2021
When omecamtiv mecarbil is used in patients who have chronic heart failure with reduced ejection fraction (HFrEF), the greater beneficial impact on clinical outcomes is seen in those with lower ejection fractions, a secondary analysis of the placebo-controlled GALACTIC-HF trial shows.
Among the prespecified subgroups in the trial, LVEF was the strongest modifier of the treatment effect, with larger reductions in the risk of HF events or CV death observed as values fell (
P = 0.004 for interaction). Reductions in NT-proBNP were greater at the lower end of the range, as well, John Teerlink, MD (San Francisco VA Medical Center and the University of California, San Francisco), reported during the recent virtual American College of Cardiology (ACC) 2021 Scientific Session. ....

Stanford University , United States , Mount Pleasant , San Francisco , Robert Harrington , John Teerlink , University Of California , American Heart Association , American College Of Cardiology , Drug Administration , Md Stanford University , Md San Francisco Va Medical Center , Journal Of The American College Cardiology , Md Central Michigan University , American College , Highly Encouraging , Central Michigan University , ஸ்டான்போர்ட் பல்கலைக்கழகம் , ஒன்றுபட்டது மாநிலங்களில் , ஏற்ற ப்லெஸெஂட் , சான் பிரான்சிஸ்கோ , ராபர்ட் ஹாரிங்டன் , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா , அமெரிக்கன் இதயம் சங்கம் , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் , ம்ட் ஸ்டான்போர்ட் பல்கலைக்கழகம் ,

Tragedy as Catalyst: How COVID-19 May Transform Clinical Research for Good


December 14, 2020
In a world indelibly changed by COVID-19 more than 72 million confirmed cases and 1.6 million deaths, and counting people and institutions have proven adaptable and resilient: look no further than the development of vaccines and the rollout now underway.
That achievement would not have been possible without improvements and acceleration in the clinical research enterprise, something also seen within cardiology research, which had to respond quickly once it became clear that COVID-19 was affecting not just the lungs, but also the heart and other organs.
This story is part of
Envision Change, an end-of-2020 series imagining a different future for cardiology, medicine, research, and health. SEE ALSO: Funding the Future, Remaking Medicine, Heroes to Human. ....

United States , United Kingdom , Robert Harrington , Alexandra Lansky , Harlan Krumholz , Bram Zuckerman , C Michael Gibson , Centers For Medicare Medicaid Services , American Heart Association , Md Yale School Of Medicine , Md Ut Southwestern Medical Center , Drug Administration , Md Stanford University , Md Baim Institute For Clinical Research , Envision Change , Yale School , New Haven , James De Lemos , Medical Center , Stanford University , Michael Gibson , Baim Institute , Clinical Research , Medicaid Services , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் ,